Shield Therapeutics reports strong H1 2025 results; Eyes cash flow positivity by year-end
LONDON: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company focused on iron deficiency, reported a sharp rise in revenues and prescription sales for the first half of 2025, as its flagship product ACCRUFeR® gained traction across key markets. Group revenues surged to $21.4 million, up 1.8 times from $12.1 million in H1 2024, driven…